Quarterly report · Q2
2372.TEDINET S100S4U1
Period2023-04-01 → 2023-09-30
Filed2023-11-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥18.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥9.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥790m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.2bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.3bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.5bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.4bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.6bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.5bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥2.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥36.2bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥35.1bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥30.4bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥23.3bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥23.0bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥13.0bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥12.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥12.0bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥8.9bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.4bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥8.9bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.4bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.0bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥803m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥17m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥4.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥740m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥90.22 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥16.56 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥210.22 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥164.17 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.8 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥210.06 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥163.91 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 35.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.2% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 62
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥250m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥219m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥31m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | −¥542m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥764m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥844m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥885m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥23m |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.4bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥610m |
| jpcrp040300-q2r_E05352-000CROreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥66m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥943m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥533m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥409m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥35m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥4.8bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥490m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.1bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥10.9bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥8.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2.4bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥2.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥11.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥8.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥68m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥28m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥39m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | −¥118m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥641m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥641m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥673m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥594m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥592m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥184m |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥88m |
| jpcrp040300-q2r_E05352-000CROreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥82m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥978m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥528m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥449m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥28m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥5.8bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.7bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥61m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥9.6bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥601m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥3.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥641m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥3.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 540
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 4779450 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.3947 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 825000 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.0681 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 597000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0493 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 123100 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0102 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 118600 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0098 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 80000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0066 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 75000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0062 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 60000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0050 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 58800 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0049 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 55100 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0046 | |
| Number of shares held | CurrentQuarterInstant | 6772050 | |
| Shareholding ratio | CurrentQuarterInstant | 0.5593 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 230800 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 11956300 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 119563 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 151265 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 12338365 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 119563 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 230800 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 230800 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0187 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 230800 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 230800 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0187 | |
| Cash and deposits | Prior1YearInstant | 9386000000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 8901000000 | JPY |
| Accounts receivable trade | Prior1YearInstant | 3389000000 | JPY |
| Accounts receivable trade | CurrentQuarterInstant | 3159000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 80000000 | JPY |
| Merchandise and finished goods | CurrentQuarterInstant | 78000000 | JPY |
| Work in process | Prior1YearInstant | 345000000 | JPY |
| Work in process | CurrentQuarterInstant | 393000000 | JPY |
| Raw materials and supplies | Prior1YearInstant | 387000000 | JPY |
| Raw materials and supplies | CurrentQuarterInstant | 378000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |